Pharma Aids (DHA:PHARMAID) Total Long-Term Assets: BDT140.3 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:PHARMAID Pharma Aids Ltd DHA:PHARMAID
73 GF Score
Price BDT606.00
GF Value BDT765.64
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Pharma Aids Total Long-Term Assets?

Pharma Aids DHA:PHARMAID -0.48% 73 Total Long-Term Assets is BDT140.3 Mil as of Mar. 2026. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT765.64 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Pharma Aids's Total Long-Term Assets for the quarter that ended in Mar. 2026 was BDT140.3 Mil.

Pharma Aids Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Pharma Aids's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Aids Total Long-Term Assets Chart

Pharma Aids Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.40 72.28 66.86 60.12 93.77

Pharma Aids Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.63 93.77 145.73 142.94 140.27
DHA:PHARMAID
73GF Score
Pharma Aids Ltd DHA:PHARMAID
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Aids Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of BDT140.3 Mil mean?
Pharma Aids (DHA:PHARMAID) has a Total Long-Term Assets of BDT140.3 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Pharma Aids and its competitors.
Is Pharma Aids' Total Long-Term Assets too high?
Pharma Aids' current Total Long-Term Assets is BDT140.3 Mil. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' Total Long-Term Assets compare to ISRG and BDX?
Pharma Aids' Total Long-Term Assets of BDT140.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Devices & Instruments company?
A good Total Long-Term Assets depends on the Medical Devices & Instruments industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Pharma Aids and its competitors. Pharma Aids's current Total Long-Term Assets is BDT140.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT765.64, compared to a current price of BDT606.00 — trading 20.9% below its estimated fair value. The current Total Long-Term Assets is BDT140.3 Mil. Pharma Aids' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current Total Long-Term Assets is BDT140.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued. The current stock price of BDT606.00 is trading 20.9% below its estimated GF Value™ of BDT765.64. GuruFocus considers Pharma Aids to be Modestly Undervalued.

Key valuation signals for DHA:PHARMAID:

  • Total Long-Term Assets: BDT140.3 Mil
  • GF Value™: BDT765.64 vs. price of BDT606.00 (20.9% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharma Aids Business Description

Address 345 Segun Bagicha, 1st Floor, Ramna, Dhaka, BGD, 1000
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score

Get the complete analysis for DHA:PHARMAID

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT606.00
Price
BDT765.64
GF Value